HK-listed Immunotech hits near 6-week high as China Resources Pharma buys stake

** Shares of Immunotech Biopharm Ltd , which makes immune cell products for cancer treatment, rise as much as 8.9% to HK$20.80, their highest since June 11

** China Resources Pharmaceutical Group Ltd says unit has agreed to buy 10% of Immunotech from Yue Cheng International Capital, Hualida Development, Ren Xiaojuan and Bei Ni Ltd for HK$799.66 mln ($102.9 mln)

** Says unit has agreed to buy 51.46 mln existing shares of Beijing-based Immunotech at HK$15.54 each, further developing its business in cellular immunotherapy

** Shares of China Resources Pharmaceutical rise 1.8%

** The Hong Kong Hang Seng Commerce & Industry Index slips 0.8%, and the healthcare index falls 1%

** The Hang Seng China Enterprises Index slides 0.7%, and the benchmark index eases 0.5%

** By last close, Immunotech shares up 71.7% this year